Ractigen Therapeutics is a clinical-stage pharmaceutical company specializing in the development of pioneering therapies that enhance the expression of therapeutic genes within diseased cells. Founded in 2017 by experts in RNA activation (RNAa) research, the company focuses on treating diseases that arise from inadequate gene expression. Ractigen operates primarily in the biotech and pharmaceutical markets, targeting previously undruggable diseases and monogenic disorders, including oncology, neurological and neuromuscular disorders, and liver-related conditions. The company's business model revolves around leveraging its proprietary RNAa technology to create a diverse pipeline of therapeutic solutions. Ractigen makes money through the development and commercialization of its innovative saRNA (small activating RNA) drugs, such as their groundbreaking drug RAG 01, which has advanced into the clinical stage. The company serves a range of clients, including patients, healthcare providers, and academic institutions, and collaborates with partners in both academia and industry to further its research and development efforts.

Keywords: RNAa, saRNA, gene activation, clinical-stage, oncology, neurological disorders, liver diseases, biotech, pharmaceutical, therapeutic solutions.